NDLI: What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles

Content Provider	Springer Nature Link
Author	Bush, Karen Page, Malcolm G. P.
Copyright Year	2017
Abstract	There are some 43 small molecules in the antibiotic development pipeline from late preclinical stage (7 compounds) through Phase 1 (11 molecules), Phase 2 (13 molecules) to Phase 3 (12 molecules). The majority of these are representatives of established antibiotic classes that have been modified to address problems of resistance. In addition, there is considerable activity around the discovery of novel classes of β-lactamase inhibitors with 10 combinations representing 4 inhibitor classes, at different stages of development. The combination of such inhibitors, which have broad activity against serine β-lactamases and may even inhibit some penicillin binding proteins, with carbapenems, cephalosporins or aztreonam, provides enhanced activity against multi-drug resistant Gram-negative bacteria. There are 6 molecules representing novel classes of antibiotics but only one of these, murepavadin, is expected to have activity against a Gram-negative pathogenic bacterium (Pseudomonas aeruginosa). Although the new analogues of existing classes, and novel combinations, have been designed to address specific resistance problems, it is by no means certain than they will not be affected by the general mechanisms of resistance, particularly decreased net flux across the Gram-negative outer membrane. The potential impact of resistance mechanisms on the new agents is assessed and the ways in which PK/PD studies are used to design dosing regimens for the new agents, especially combinations, as well as to improve dosing of existing antibiotics are discussed.
Starting Page	113
Ending Page	132
Page Count	20
File Format	PDF
ISSN	1567567X
Journal	Journal of Pharmacokinetics and Pharmacodynamics
Volume Number	44
Issue Number	2
e-ISSN	15738744
Language	English
Publisher	Springer US
Publisher Date	2017-02-04
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Antibiotics Development Pipeline Resistance Pharmacodynamics Pharmacology/Toxicology Pharmacy Veterinary Medicine/Veterinary Science Biomedical Engineering Biochemistry
Content Type	Text
Resource Type	Article
Subject	Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects

Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives

Approaches to handling pharmacodynamic baseline responses

Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children

Assessment of Basic Indirect Pharmacodynamic Response Models with Physiological Limits

Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans

Array of translational systems pharmacodynamic models of anti-cancer drugs

Investigation of a Cellular Pharmacodynamic Model Exhibiting Sharp Response Sensitivity and Tolerance

Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models

What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles

Similar Documents

Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects

Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives

Approaches to handling pharmacodynamic baseline responses

Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children

Assessment of Basic Indirect Pharmacodynamic Response Models with Physiological Limits

Pharmacodynamic Models for Agents that Alter Production of Natural Cells with Various Distributions of Lifespans

Array of translational systems pharmacodynamic models of anti-cancer drugs

Investigation of a Cellular Pharmacodynamic Model Exhibiting Sharp Response Sensitivity and Tolerance

Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models

What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles